Hold ABT — Structural floor intact but overbought; add only on $110-113 pullback or >$117 breakout
Maintain ABT at Hold. The structural thesis is intact—200 SMA flipped to support, golden cross forming in 2-6 weeks, MiniMed CGM shipping, Q1 2026 was one-time integration trough, $7B FCF, Dividend Aristocrat—but the current tactical setup offers no margin of safety at RSI 77.97 with bearish divergence, MACD histogram collapsed 75% from peak, and price at upper Bollinger band $117.03. Add only on confirmed pullback to $110-113 or breakout above $117.03 on volume >7M; stop at $105.84 (tighten to $108 if integration disappoints). Trim 10-15% if price extends above $117 before Sep 16 FOMC.
| Position | Action |
|---|---|
| Current position at 1.5-2.5% portfolio weight | Maintain current weight; do not add |
| Price pullback to $110-113 with confirmed higher-low structure and RSI reset toward 50-55 | Add position |
| Daily close above $117.03 on volume >7M with RSI pushing toward 80 | Asymmetric add 2-3% portfolio on the close |
| Price pushes above $117 before Sep 16 FOMC | Trim 10-15% into strength |
| Integration commentary disappoints | Tighten stop to $108 |
The evidence overwhelmingly supports a bullish structural stance on Abbott Laboratories at current levels, with technical momentum, fundamental catalysts, and macro regime all aligning in favor of bulls; ABT is a buy on meaningful dips and a hold with conviction at current levels.
| Indicator | Value | Signal |
|---|---|---|
| Close | $116.67 | neutral |
| 10 EMA | $113.03 (Price +3.2% above) | bullish |
| 50 SMA | $100.21 (Price +16.4% above) | bullish |
| 200 SMA | $105.84 (Price +10.2% above) | bullish |
| RSI | 77.97 | bearish |
| RSI (2026-07-14) | 41.96 | neutral |
| MACD | +4.343 | bullish |
| MACD Histogram (2026-08-24) | +0.275 | bearish |
| MACD Histogram Peak (2026-07-29) | +1.108 | bearish |
| Bollinger Upper Band | $117.03 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Daily close above $117.03 on volume >7M shares with RSI pushing toward 80
Then: Asymmetric 2-3% portfolio add on the close
The $670M NEC settlement removes a binary litigation overhang, converting it to a known manageable cost that enables multiple re-rating rather than representing value destruction
↩ rebuts: “Bear treating settlement as cash outflow headwind rather than risk removal”
EV: DCF reads 2% undervalued · concedes: RSI at 77.97 = overbought (argued normal in catalyst uptrend; trail stops not fade); MACD histogram divergence (argued MACD still positive and rising); $20B net debt increase (argued 15x interest coverage; $7.21B FCF; integration trough is Q1 2026 in rearview); Q1 2026 EPS down 20% YoY (argued Q1 2026 IS the trough; acquisition financing closed Q1; unwinding noise going forward); No retail buzz (argued smart money accumulation confirms; compounder not meme stock)
Abbott's 43% rally has exhausted its upside; the stock now sits overbought at 19x forward P/E with negative tangible book value, 6x leverage, and no margin of safety to absorb integration disappointment or macro headwinds.
EV: -5% to -6% · concedes: MiniMed Flex is a positive development and sensor pull-through has value; MACD itself remains positive, not bearish; Citadel position disclosure suggests at least some institutional conviction; The 200 SMA at $105.84 has shown support
→ vs conservative: Waiting for $110 to $113 pullback is anchoring to a level institutional buyers are already defending, guaranteeing underperformance in a fresh structural breakout
→ vs conservative: RSI 77.97 overbought reading is not a sell signal—it's a checklist item for adding, not exiting, especially with the largest volume signature in the dataset confirming the move
→ vs conservative: ABT's 0.58 beta means hawkish Fed scenarios crush long-duration speculative growth names, not diversified medical device compounders with 2.16% dividend yield
→ vs neutral: PEG of 2.35 is a flawed metric when applied to a $20 billion liability that suppresses near-term earnings by 20%—forward P/E of 19x is appropriate for normalized earnings
→ vs neutral: Multiple expansion comes when uncertainty resolves, and it just did with the $670 million settlement
→ vs conservative: If conservative view prevails and investors wait for 110, there's real risk of waking up at 125 and having to chase the position
| Bollinger Middle Band (20 SMA) | $109.87 | bullish |
| Bollinger Lower Band | $102.70 | neutral |
| Bollinger Bandwidth | $14.33 | neutral |
| ATR | $2.56 | neutral |
| ATR Peak (2026-07-17) | ~$3.15 | neutral |
| 1× ATR Stop Loss | $114.11 | neutral |
| 1.5× ATR Stop Loss | $112.83 | neutral |
| 2× ATR Stop Loss | $111.55 | neutral |
| Suggested Trailing Stop | ~$112.80 | neutral |
| Bullish Invalidation Level | <$105.84 (200 SMA) | bearish |
Support: 113.03 · 109.87 · 105.84 · 100.21 | Resistance: 117.03 · 120
ABT is in a structural uptrend with all moving averages positively stacked beneath price ($116.67), having rallied +18% in 29 trading sessions since the July 16 gap-up catalyst. Key resistance sits at $117.03 (Bollinger upper band) and ~$120 (prior support zone from late 2025). Overbought RSI (77.97) with a bearish histogram divergence and price pressing the upper band suggest caution for new longs; the recommendation is to HOLD existing positions with a trailing stop at ~$112.80, adding only on pullbacks to $110-$113 or a confirmed breakout above $117.03 with volume.
Market Cap
$201.88 B
Ticker
ABT
Current Price
~$115.80
52-Week Range
$81.97 – $137.49
50-Day Avg
$99.94
200-Day Avg
$107.08
Beta
0.58
Dividend Yield
2.16%
FY2025 Revenue
$44.33 B
FY2025 Net Income
$6.52 B
FY2025 Diluted EPS
$3.72
FY2024 Net Income (reported)
$13.40 B
FY2024 Diluted EPS (reported)
$7.64
TTM Revenue (Q1 2026)
$46.58 B
Q1 2026 Revenue
$11.16 B
Q1 2026 Operating Income
$1.35 B
Q1 2026 Net Income
$1.08 B
Q1 2026 Diluted EPS
$0.61
Q1 2026 Acquisition Cost
$19.798 B
Gross Profit (TTM)
$26.48 B
Gross Margin
~56.8%
EBITDA
$11.68 B
Operating Margin
14.7%
Net Margin
11.6%
ROE
10.6%
ROA
5.3%
Interest Expense (annualized)
~$700 M
Total Assets (Q1 2026)
$110.4 B
Total Equity (Q1 2026)
$52.7 B
Total Debt (Q1 2026)
$34.0 B
Net Debt (Q1 2026)
$27.2 B
Goodwill (Q1 2026)
$35.22 B
Other Intangibles (Q1 2026)
$17.88 B
Current Ratio (Q1 2026)
1.38
Working Capital (Q1 2026)
$7.13 B
Debt-to-Equity
~0.65
Interest Coverage
~15x
Tangible Book Value
$-1.04 B
FCF (TTM)
$7.21 B
Annual Dividends
~$4.4 B
Q1 2026 Dividends Paid
$1.098 B
P/E (TTM)
37.76x
Forward P/E
19.24x
PEG Ratio
2.35
Price/Book
3.95x
Price/Sales (TTM)
~4.3x
Strengths
Concerns
Abbott Laboratories completed a transformational ~$20B all-debt acquisition in Q1 2026, tripling total assets to $110.4B and increasing net debt 6x to $27.2B, with nearly half of assets now comprised of goodwill and intangibles. Near-term profitability is significantly compressed—Q1 2026 EPS declined ~20% YoY due to integration costs, SG&A up 22% YoY, and ~$54M/quarter in incremental interest expense—though the underlying business remains healthy with 7.8% YoY revenue growth, $7.21B TTM free cash flow, and strong 15x interest coverage. The stock trades at a fair ~19x forward P/E (vs misleading 37.8x TTM) with a 2.16% dividend yield and defensive 0.58 beta, positioning it as a balanced but slightly positive risk/reward for patient investors over a 12-24 month horizon.
Macro: Fed hawkish hold: 66% probability of hold at Sept 2026 meeting (-5 pp 1-week), 34% probability of 25-bp hike (+6 pp 1-week), 1% probability of 25-bp cut (+0.4 pp 1-week). Bond market pricing higher odds of hike than cut — meaningful hawkish shift. December 2026: 12% priced for any cut by year-end (-2 pp). Inflation tails fading but elevated: 14% odds inflation >4.5%, 6% >5.0%, 4% >6.0%. Soft-landing consensus firmed: US recession 8% by end-2026 (down materially), UK 12%, Japan 22% (-32 pp). Gold settled +0.36% at $4,640.80/oz; Silver +18% MoM. Macro regime: sticky but moderating inflation with Fed willing to keep policy restrictive.